{"entity":{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","aka":[],"tldr":"Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery.","summary":"Jeanne Tie led DYNAMIC, which showed that using ctDNA to decide adjuvant chemotherapy in stage II colon cancer halves chemotherapy use without worsening recurrence-free survival, the first randomised proof that ctDNA-guided de-escalation works. Her 2016 study established post-operative ctDNA as a powerful marker of residual disease. She now leads DYNAMIC-III and DYNAMIC-Rectal.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tie%20J%5BAuthor%5D%20ctDNA%20colon"}],"tags":["ctdna","colorectal","de-escalation"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":["signatera"],"companies":[],"institutions":["wehi","peter-mac"],"pathways":[],"terms":[],"trials":["dynamic","circulate-japan"],"people":[],"bottlenecks":[],"keyPapers":["paper-dynamic-nejm-2022","paper-galaxy-signatera-nat-med-2023"],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Peter MacCallum Cancer Centre; Laboratory Head, Walter and Eliza Hall Institute","institutionId":"wehi","specialisms":["Circulating tumour DNA","Colorectal cancer","Adjuvant therapy","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tie%20J%5BAuthor%5D%20ctDNA%20colon"}],"papers":[{"title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2200075"},{"title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","journal":"Science Translational Medicine","year":2016,"doi":"10.1126/scitranslmed.aaf6219"},{"title":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","journal":"Nature Medicine","year":2023,"url":"https://doi.org/10.1038/s41591-022-02115-4","doi":"10.1038/s41591-022-02115-4"}],"orcid":"0000-0001-9244-2057"},"route":"/people/jeanne-tie/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/"}],"trial":[{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/"},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/"}],"paper":[{"id":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","kind":"paper","name":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","route":"/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/"},{"id":"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","kind":"paper","name":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","route":"/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/"},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/"},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/"}],"journal":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}